1. EachPod
EachPod

Advancements in the Field of Oncology with Richard L. Schilsky, MD

Author
Healio
Published
Mon 21 Mar 2022
Episode Link
http://oncologyoverdrive.libsyn.com/advancements-in-the-field-of-oncology-with-richard-l-schilsky-md

In this episode, Richard L. Schilsky, FSCT, FASCO, FACP, MD, discusses his involvement with ASCO, ideas for making a more equitable health care system and thoughts on the current state of oncology.

  • Welcome to another exciting episode of Oncology Overdrive :13
  • About Schilsky :24
  • The interview 2:50
  • How did you end up in medicine, in oncology and then in GI oncology? What was your path into this space? 3:01
  • What was it that drew you to becoming involved in ASCO and seeing where your journey would lie in that space? 9:15
  • What is something that surprised you in oncology in your career? Is there anything you can look back and think that was really shocking, or that was a major development that you never could have imagined happening in the cancer space? 14:14
  • How has COVID impacted what you've seen for your patients and your colleagues? 23:04
  • What do we need to do to work towards a more equitable health care system and more equitable cancer care for our patients? 28:07
  • Looking back at your career, do you think where we are now is where you expected? 33:24
  • If somebody could only listen to the last 2 minutes of this episode, what would you want them to take away? 40:11
  • How to contact Dr. Schilsky 41:26
  • Thanks for listening 42:13

Richard L. Schilsky, FSCT, FASCO, FACP, MD, is the former chief medical officer and executive vice president of ASCO. He is also the former chief of hematology/oncology in the Department of Medicine and deputy director of the University of Chicago Comprehensive Cancer Center.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow us on Twitter @HemOncToday and @ShikhaJainMD.

Disclosures: Jain reports she is a paid freelance writer for Lippincott. Schilsky reports no relevant financial disclosures.

Share to: